Amyl Therapeutics has raised €8.25m to generate preclinical data for its pan-amyloid therapy targeting Alzheimer’s, Parkinson’s and related diseases.

Funding will support next development stage

The Belgian biotechnology company has completed an €8.25m extension of its Series A financing, bringing its total funding to €27.85m.

Half of the latest financing comes from public grants, with the remainder provided by new private investors, including family offices and business angels, as well as existing shareholders Noshaq and Mérieux Equity Partners.

Amyl Therapeutics said the funding will support completion of its lead clinical candidate and the remaining preclinical efficacy and safety studies required to advance its platform.

The company said its clinical candidate is fully characterised and ready for GMP manufacturing, while the next stage of development will focus on generating in vivo data.

Pierre Vandepapelière, co-founder, CEO and CMO of Amyl Therapeutics, said: “This financing is an important endorsement of both our science and our vision. We are deeply grateful for the continued confidence shown by our investors and public partners, whose support enables us to reach the next critical stage of our development.”

The financing will also support an expansion of Amyl Therapeutics’ research operations, including laboratory facilities at the LegiaPark life sciences campus in Liège and a doubling of its R&D team.

Fusion protein targets multiple amyloid aggregates

Amyl Therapeutics is developing a fusion protein designed to recognise a common amyloid structure found across several pathological protein aggregates.

The company is targeting amyloid beta, tau and alpha-synuclein, which are associated with Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders.

The approach differs from antibody therapies that target individual pathological proteins. Amyl Therapeutics aims to use a single therapy against the shared amyloid structure rather than developing separate treatments for each protein.

The platform also incorporates a “brain shuttle” technology designed to improve transport of the fusion protein across the blood-brain barrier.

Delivery of biological medicines into the brain is a major challenge in the development of treatments for neurodegenerative diseases. Amyl Therapeutics is therefore investigating whether its approach can improve brain exposure while maintaining an acceptable safety profile.

The company has also engineered its therapeutic candidate to reduce the risk of amyloid-related imaging abnormalities (ARIA) and anaemia associated with some existing anti-amyloid beta antibody treatments.

However, these potential safety benefits remain to be demonstrated through further preclinical and clinical development.

In vivo studies are next milestone

The €8.25m financing will support the generation of in vivo efficacy and safety data needed to further validate the platform.

These studies are preclinical and will precede any clinical testing of the company’s candidate.

Amyl Therapeutics said its longer-term objective is to progress the candidate towards GMP manufacturing and clinical development for neurodegenerative diseases.

The company has previously raised €10.8m at launch in 2021, including €5.1m in-kind funding associated with the acquisition of its intellectual property and €2.2m in non-dilutive grants.

A further €5m was provided by shareholders during 2023 and 2024, alongside €3.8m in non-dilutive support from the Walloon Region of Belgium.

The latest financing brings total funding raised by Amyl Therapeutics to €27.85m.

The company said a new lead family office investor will also join its board of directors as part of the financing.